Navigation Links
Covance Board Authorizes $250 Million Stock Buyback
Date:9/28/2010

PRINCETON, N.J., Sept. 28 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) said today that its Board of Directors has authorized the repurchase of up to $250 million of its outstanding common stock. This authorization is in addition to the approximately 800,000 shares remaining under the repurchase authorization announced in 2007 and currently represents nearly ten percent of the Company's common stock. Any purchases under this buyback would be dependent upon business and market conditions and other factors. The stock purchases may be made from time to time and may be made through a variety of methods including open market purchases, privately negotiated transactions, block trades, and 10b5-1 plans.

"This action reflects the confidence of the Board and management in the fundamental strengths and future outlook of Covance," said Joe Herring, Chairman and Chief Executive Officer of Covance.

About Covance

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.8 billion, global operations in more than 30 countries, and more than 10,000 employees worldwide.  Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release, which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, risks associated with acquisitions and investments, and the Company's ability to increase order volume, the pace of translation of orders into revenue in late-stage development services, and other factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no duty to update any forward looking statement to conform the statement to actual results or changes in the Company's expectations.


'/>"/>
SOURCE Covance Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
2. Covance Receives Highest Level of Phase I Accreditation
3. Covance Inc. Invites You to Join the Webcast of Its Fourth Quarter 2009 Financial Results Conference Call
4. Covance to Present at the 28th Annual J.P. Morgan Healthcare Conference
5. Rules-Based Medicine Forms Biomarker Alliance With Covance Inc.
6. Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc.
7. Covance to Present at Piper Jaffray 21st Annual Health Care Conference
8. Covance To Present At The 20th Annual Global Healthcare Services Conference
9. Covance To Present at the Deutsche Bank 35th Annual Health Care Conference
10. Covance to Present at Goldman Sachs 31st Annual Global Healthcare Conference
11. Covance to Present at William Blair & Companys 30th Annual Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)...   Science Exchange , the leading marketplace ... the first five replication studies from the ... in eLife today. Despite intense scrutiny around reproducibility ... evaluation of reproducibility rates that may identify specific ... assessments of reproducibility, the results of this project ...
(Date:1/19/2017)... January 18, 2017 , , Marks E-QURE ... distribution agreement, following similar agreements in Israel ... Wound care is $2 5 billion ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of ... Médica Equipos Médicos S.A.S. (TeckMedica) in Colombia for the ...
(Date:1/19/2017)... , Jan. 18, 2017 The drug ... billion by 2021 from USD 1,179.20 billion in 2016, ... Increasing prevalence of chronic diseases, increasing demand for ... factors driving the growth of this market. Whereas, self-administration ... generic drugs offer significant growth opportunities for players operating ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... ... With the cold weather here, many people will have to clear snow with snow blowers ... of snow, but they can be dangerous when used incorrectly. That’s why Amica Insurance ... proper use of snow blowers:, , When removing wet snow or ...
(Date:1/19/2017)... ... ... Cosmetic Town, an online plastic surgery community, begins 2017 with an update ... their readers to get the information they desire. The procedures are now listed according ... on those particular areas. , “We are excited to streamline our listings in a ...
(Date:1/19/2017)... ... 2017 , ... Bio-Optronics Inc. is proud to announce the ... to seamlessly integrate and streamline the way researchers prepare and conduct patient visits. ... and improving efficiency significantly for users – a first in the CTMS industry. ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... staff members in 2017 who are passionate about making a difference in the ... and headquartered in Tampa, UMA, a nonprofit healthcare educational institution, has more than ...
(Date:1/19/2017)... ... 2017 , ... For the third year running, Noto Insurance ... surrounding area, is inaugurating a charity event to help raise funds for ... Gehrig's disease or motor neurone disease, is a deadly neurological disorder that affects ...
Breaking Medicine News(10 mins):